Recognition and Management of Diabetic Neuropathy

Primary Care - Clinics in Office Practice

Volumn 34, Issue 4, 2007, Pages 887-913

  Unger, Jeff ^a   Cole, B Eliot ^b  

^a Diabetes and Headache Intervention Center   (United States)

^b American Society of Pain Educators   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 ALPHA FLUOROHYDROCORTISONE; AMFEBUTAMONE; AMITRIPTYLINE; ANALGESIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPSAICIN; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DULOXETINE; FLUDROCORTISONE; GABAPENTIN; LAMOTRIGINE; LIDOCAINE; MAGNESIUM OXIDE; METHADONE; NORTRIPTYLINE; OXYCODONE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RIFAMPICIN; THIOCTIC ACID; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

AMNESIA; AMPUTATION; ANXIETY; ATAXIA; AUTONOMIC NEUROPATHY; BEDTIME DOSAGE; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN TOXICITY; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIARRHEA; DISABILITY; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRY EYE; DYSPEPSIA; ECONOMIC ASPECT; EDEMA; EMOTION; ENCEPHALITIS; FATIGUE; FOOT CARE; GLYCEMIC CONTROL; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; INTERVENTION STUDY; LIFE; LIFESTYLE; NAUSEA; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PAIN; PATHOGENESIS; PATIENT EDUCATION; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK; SCREENING; SEDATION; SEIZURE; SENSORIMOTOR NEUROPATHY; SIDE EFFECT; SILENT MYOCARDIAL ISCHEMIA; SLEEP DISORDER; SLURRED SPEECH; SMOKING CESSATION; SOCIAL ASPECT; SOMNOLENCE; SWEATING; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION; MASS SCREENING; OXIDATIVE STRESS; PROTEIN KINASE C; RISK FACTORS;

EID: 36549047430     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2007.07.003     Document Type: Review

References (48)

1. Vinik A.I., and Mehrabyan A. Understanding diabetic neuropathies. Emerg Med 5 (2004) 39-44
2. Carrington A.L., Abbott C.A., Shaw J.E., et al. Can motor nerve conduction velocity predict foot problems in diabetic neuropathy over a 6-year outcome period?. Diabetes Care 25 (2002) 2010-2015
3. Boulton A.J.M., Gries F.A., and Jervell J.A. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 15 (1998) 508-514
4. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Metab 3 (1977) 97-107
5. Vinik A.I., Maser R.E., Mitchell B.D., et al. Diabetic autonomic neuropathy. Diabetes Care 26 (2003) 1553-1579
6. Boulton A.J.M., Malik R.A., Arezzo J.C., et al. Diabetic somatic neuropathies. Diabetes Care 27 (2004) 1458-1486
7. Argoff C.E., Cole B.E., Fishbain D.A., et al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 81 4 suppl (2006) S3-S11
8. Yagihashi S., Kamijo M., and Watanabe K. Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats. Am J Pathol 136 (1990) 1365-1373
9. Perkins B.A., Greene D.A., and Bril V. Glycemic control is related to the morphological severity of diabetic sensorimotor polyneuropathy. Diabetes Care 24 (2001) 748-752
10. Tkac I., and Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. Diabetes Care 21 (1998) 1749-1752
11. Boulton A. The diabetic foot: a global view. Diabetes Metab Res Rev 16 (2000) S2-S5
12. Bild D.E., Selby J.V., Sinnock P., et al. Lower extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care 12 (1989) 24-31
13. Gordois A., Scuffham P., Shearer A., et al. The health care costs of peripheral neuropathy for people with diabetes in the U.S. Diabetes Care 26 (2003) 1790-1795
14. Introduction to diabetes. In: Unger J. (Ed). Diabetes management in primary care (2007), Lippincott, Williams and Wilkins, Philadelphia 1-42
15. Gore M., Brandenburg N.A., Dukes E., et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 30 4 (2005) 374-385
16. Vlassara H., and Palace M.R. Diabetes and advanced glycation endproducts. J Intern Med 251 (2002) 87-101
17. Baynes J.W., and Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48 (1999) 1-9
18. Meier M., and King G.L. Protein kinase C activation and its pharmacological inhibition in vascular disease. Va Med 5 (2000) 173-185
19. Monnier L., Mas E., Ginet C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006) 1681-1687
20. Brownlee M., and Hirsch I.B. Glycemic variability: a hemoglobin A1C-independent risk factor for diabetic complications. JAMA 295 (2006) 1707-1708
21. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
22. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44 (1995) 968-983
23. Watkins L.R., Milligan E.D., and Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci 24 (2001) 450-455
24. del Zoppo J.G. Stroke and neurovascular protection. N Engl J Med 354 (2006) 553-555
25. Koehler R.C., Gebremedhin D., and Harder D.R. Role of astrocytes in cerebrovascular regulation. J Appl Physiol 100 (2006) 307-317
26. Watkins L.R., and Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2 (2003) 973-985
27. Vallejo R., de Leon-Casasola O., and Ramsun B. Opioid therapy and immunosuppression: a review. Am J Ther 11 (2004) 354-365
28. Pfeifer M.A., Weinberg C.R., Cook D.L., et al. Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 7 (1984) 447-453
29. Ziegler D., Gries F.A., Muhlen H., et al. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes center. The DiaCAN Multicenter Study Group. Diabetes Metab 19 (1993) 143-151
30. Kahn J., Zola B., Juni J., et al. Decreased exercise heart rate in diabetic subjects with cardiac autonomic neuropathy. Diabetes Care 9 (1986) 389-394
31. Unger J. Diabetic neuropathy: early clues, effective management. Applied Neurology 1 9 (2005) 23-30
32. Valensi P., Sachs R.N., Harfouche B., et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 24 (2001) 339-343
33. Freeman R., Saul P., Roberts M., et al. Spectral analysis of heart rate in diabetic autonomic neuropathy. Arch Neurol 48 (1991) 185-190
34. Vinik A.I., Erbas T., Pfeifer M.A., et al. Diabetic autonomic neuropathy. In: Porte D., Sherwin R.S., and Baron A. (Eds). Ellenberg & Rifkin's diabetes mellitus. 6th edition (2003), McGraw Hill, New York 789-804
35. Maser R.E., Mitchell B.D., Vinik A.I., et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 26 (2003) 1895-1901
36. Maleki D., Locke III G.R., Camilleri M., et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 160 (2000) 2808-2816
37. Vinik A., Erbas T., and Stansberry K. Gastrointestinal, genitourinary, and neurovascular disturbances in diabetes. Diabetes Reviews 7 (1999) 358-378
38. Bacon C.G., Hu F.B., Giovannucci E., et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 25 (2002) 1458-1463
39. Shaw J.E., Parker R., Hollis S., et al. Gustatory sweating in diabetes mellitus. Diabet Med 13 (1996) 1033-1037
40. Cryer P.E. Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab 281 (2001) E1115-E1121
41. DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 41 (1998) 416-423
42. Gaede P., Vedel P., Parving H.H., et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999) 617-622
43. Ziegler D., Reljanovic M., Mehnert H., et al. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 107 (1999) 421-430
44. Ebbehoj E., Poulsen P.L., Hansen K.W., et al. Effects on heart rate variability of metoprolol supplementary to on going ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia 45 (2002) 965-975
45. Unger J., and Marcus A. Insulin pump therapy. What you need to know. Emerg Med 34 9 (2002) 24-33
46. Restivo D.A., Lanza S., Patti F., et al. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology 59 (2002) 1971-1973
47. Berger A., Dukes E.M., and Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 5 (2004) 143-149
48. Argoff C.E., Backonja M.M., Belgrade M.J., et al. Consensus guidelines: treatment planning and options. Mayo Clin Proc 81 suppl 4 (2006) S12-S25